Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
C3 Glomerulopathy: later-stage trial registry
2 of 4 indexed C3 Glomerulopathy trials are currently recruiting, with more weight in Phase 3-4.
Corpus placement: #4,115 of 28,707 conditions by registered trial count.
4 US clinical trials · 2 currently recruiting · #4,115 of 28,707 conditions by registered trial count
C3 Glomerulopathy: 4 US clinical trials tracked, 2 recruiting.
C3 Glomerulopathy is the subject of 4 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Apellis Pharmaceuticals, running 2 of these trials.
Enrollment posture brief
Registry condition c3-glomerulopathy
OPEN 2 | RECR 50% | LATE 2 | EARLY 1 | RANK #4115 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Abdominal Aortic Aneurysms (50% recruiting · 6 trials)
C3 Glomerulopathy lists 2 open slots (50% of 4 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for C3 Glomerulopathy on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
C3 Glomerulopathy is recruiting above its size-band peers.
2 of 4 indexed trials (50%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
4 total, page 1 of 1
Long-term Efficacy, Safety and Tolerability of Iptacopan in C3G or IC-MPGN
Novartis Pharmaceuticals
NCT03955445
Home Reported Outcomes in C3G Study
Novartis Pharmaceuticals
NCT07029542
An Open-Label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan in Participants With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis
Apellis Pharmaceuticals
NCT05809531
Study Assessing the Safety and Efficacy of Pegcetacoplan in Post-Transplant Recurrence of C3G or IC-MPGN
Apellis Pharmaceuticals
NCT04572854
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 1 |
| Phase 3 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on C3 Glomerulopathy records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on C3 Glomerulopathy trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this C3 Glomerulopathy page
4 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 2 C3 Glomerulopathy trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Apellis Pharmaceuticals sponsors the most C3 Glomerulopathy trials on record, review their full trial history before evaluating a specific study. See Apellis Pharmaceuticals's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This C3 Glomerulopathy condition card totals 4 registered trials; most-linked intervention Pegcetacoplan; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.